Ayala is a clinical-stage oncology company founded in November 2017 after acquiring an exclusive, worldwide license to our product candidates AL101 and AL102 from Bristol-Myers Squibb (BMS). We are focused on developing and commercializing small molecule therapeutics for patients living with rare and aggressive cancers, especially in genetically defined patient populations.
Our development approach is rooted in identifying and addressing indications in which Notch-pathway activation is known to be a tumorigenic driver. We use a combination of next-generation sequencing and our bioinformatics platform to help develop Notch-targeted therapies to underserved patient populations. Advances in molecular testing and sequencing have enabled the discovery of Notch-activating mutations in multiple tumor types – providing us with additional tools to identify patients who are most likely to respond to the gamma secretase inhibitors we develop.
By developing gamma secretase inhibitors, or drugs designed to inhibit Notch-pathway activation, we believe we can enable personalized therapy for cancer patients. Currently, we have two investigational product candidates in development for a variety of tumors:
Adenoid Cystic Carcinoma (ACC)
Triple Negative Breast Cancer (TNBC)
T-cell Acute Lymphoblastic Leukemia (T-ALL)
Multiple Myeloma (MM) in collaboration with Novartis
Interested in learning more about the people who make up Ayala? Meet our team of dedicated biotech leaders, scientists, oncologists, and other experts working every day to advance therapies for people living with rare and aggressive cancers.